The value of medical innovation versus industry rewards
Given the rapid growth in healthcare spending that is often attributed to technological change, many private and public institutions are grappling with how to...
Dr. Kristopher Hult is a principal in the Antitrust & Competition Economics Practice of Charles River Associates. He is an experienced antitrust economist specializing in applying economic principles and data analysis to complex issues at the intersection of antitrust and healthcare.
His expertise encompasses a broad spectrum of antitrust cases, ranging from biosimilar entry, rebate traps in pharmaceuticals, damages resulting from patent infringement, and health insurance mergers. He regularly provides highly technical data analysis to a variety of complex datasets such as insurance claims, patient enrollment, financial, and patient treatment history data.
He also has significant experience in estimating damages stemming from allegations of collusion in a variety of markets and antitrust issues in regulated markets, such as railroads and public utilities. His work in all of these areas consistently withstands the scrutiny and rigor of complex litigation because it is based on providing answers that are consistent with both data and economic theory while helping clients achieve their desired results. As an experienced writer and speaker, he has made significant contributions to the economics of pharmaceutical innovation and personalized medicine including publications in academic journals and book chapters.
Prior to joining CRA, Dr. Hult completed his doctoral studies in economics at the University of Chicago. He has published and presented academic research on quantifying the impact of medical innovation and technological change.